New York – June 9, 2026 – Cooley advised the underwriters of Tango Therapeutics (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, on Tango's $600 million upsized public offering. The offering consisted of an underwritten offering of 18,166,667 shares of its common stock priced at $30 per share and pre-funded warrants to purchase up to 1,833,395 shares of its common stock priced at $29.999 per share. Tango has also granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount.

J.P. Morgan, Leerink Partners, Cantor and Stifel are acting as joint bookrunning managers for the offering.

The Cooley capital markets team included partners Evan Leitner, Darah Protas, Daniel Goldberg and Richard Segal and associates Eric Delgado, Matthew Iannone and Zachary Polen.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.